CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended		119 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
Cash flows from operating activities
Net loss	$ (8,930,833)	$ (5,968,448)	$ (109,611,620)
Adjustments to reconcile net loss to net cash used in operating activities
Stock payable for acquired research and development			112,440
Stock issued for acquired research and development			26,286,589
Stock issued for services		87,028	2,061,743
Stock issued for debt in excess of principal			109,070
Amortization of discount on notes payable due to warrants and beneficial conversion feature	104,032		6,856,730
Gain on extinguishment of debt			(1,612,440)
Depreciation	303,677	210,252	1,650,158
Amortization of debt financing costs	58,639		583,017
Option and warrant expense	690,726	489,914	16,265,933
Gain on derivative instruments	(552,978)		(1,941,826)
Loss on disposal of fixed assets	3,097	9,686	513,345
Changes in:
Other current assets	(611,607)	(39,248)	(1,153,053)
Accounts payable - third parties and related parties	(71,410)	(13,028)	(160,651)
Accrued expenses	83,018	234,923	605,238
Net cash used in operating activities	(8,923,639)	(4,988,921)	(59,435,327)
Cash flows from investing activities
Purchase of property & equipment	(550,389)	(296,949)	(2,222,199)
Restricted cash	(1,000,000)		(1,000,000)
Net cash used in investing activities	(1,550,389)	(296,949)	(3,222,199)
Cash flows from financing activities
Common stock and warrants sold for cash, net of offering costs	381,309	8,618,157	49,453,797
Common stock repurchased and canceled			(325)
Proceeds from exercise of warrants and options			1,248,588
Proceeds from third party debt	3,455,000		12,738,184
Proceeds from related party debt	630,000		630,000
Deferred financing and offering costs	(509,492)		(509,492)
Repayments on loan payable		(35,607)	(311,222)
Net cash provided by financing activities	3,956,817	8,582,550	63,249,530
Net change in cash and cash equivalents	(6,517,211)	3,296,680	592,004
Cash and cash equivalents at beginning of period	7,109,215	3,812,535
Cash and cash equivalents at end of period	592,004	7,109,215	592,004
Cash paid for:
Income tax
Interest	1,946	3,135	155,109
NON-CASH TRANSACTIONS
Issuance of common stock to Sportan shareholders			147,733
Issuance of common stock for accrued interest	185,683		789,287
Issuance of warrants to placement agent			37,453
Conversion of notes payable to common stock			7,709,980
Conversion of accrued liabilities to common stock			197,176
Conversion of accounts payable to note payable			93,364
Discount on convertible notes relating to:
Warrants	2,314,635		5,974,372
Beneficial conversion feature	1,497,634		3,303,153
Stock attached to notes			1,287,440
Fair value of derivative instrument			4,680,220
Derivative reclassified to equity	1,761,657		2,349,266
Unpaid additions to property and equipment	7,812	136,266	144,078
Amortization of deferred offering costs to paid-in capital	$ 47,339		$ 47,339
Shares issued as deferred offering costs	149,131		149,131